Ocrevus Side Effects, Infusion Time, and MS Treatment Guide

Ocrevus (ocrelizumab) is an intravenous infusion for relapsing and primary progressive multiple sclerosis, given just twice a year after an initial split dose. Infusions last 2.5 to 3.5 hours with required premedication. Common side effects include infusion reactions, upper respiratory infections, and skin infections, with rare PML risk requiring monitoring.

The Twice-a-Year Treatment That Changed MS Care

For people living with multiple sclerosis, the rhythm of treatment often defines daily life. Daily pills, weekly injections, monthly infusions — each option comes with its own disruptions. So when Ocrevus arrived with its twice-a-year dosing schedule, it represented something many MS patients had not experienced before: long stretches of time where treatment simply was not something they had to think about.

Approved by the FDA in 2017, ocrelizumab was also the first therapy specifically approved for primary progressive MS (PPMS), a form of the disease that had few treatment options for decades. That dual approval — for both relapsing MS and PPMS — made Ocrevus one of the most significant additions to MS treatment in years. Today it is among the most widely prescribed infusion therapies for multiple sclerosis in the United States.

How Ocrevus Works

Ocrevus is a monoclonal antibody that targets CD20, a protein found on the surface of certain B cells (a type of white blood cell). In multiple sclerosis, B cells play a role in driving the autoimmune attack on the myelin sheath, the protective coating around nerve fibers in the brain and spinal cord. By selectively depleting CD20-positive B cells, ocrelizumab reduces the immune-mediated damage that causes MS relapses and disease progression.

Importantly, Ocrevus does not eliminate all B cells. It spares earlier-stage B cells (pro-B cells) and later-stage plasma cells, which are responsible for maintaining long-term immunity from past infections and vaccinations. Still, because the drug significantly reduces a major immune cell population, infection risk is an important consideration that the National MS Society emphasizes in its patient education materials.

Dosing Schedule and the Split First Dose

Ocrevus uses a unique dosing approach for the initial treatment:

The initial dose is split into two 300 mg infusions given two weeks apart. This approach helps reduce the risk and severity of infusion reactions during the first exposure. After that, patients receive a single 600 mg infusion every six months. Each subsequent infusion takes approximately 3.5 hours, though some centers now offer a shorter infusion option (approximately 2 hours) for patients who have tolerated previous infusions without significant reactions.

What to Expect During an Ocrevus Infusion

Premedication is required before every Ocrevus infusion. The standard protocol includes:

• Methylprednisolone 100 mg IV (or equivalent corticosteroid), given approximately 30 minutes before the infusion
• Diphenhydramine (Benadryl) — an antihistamine given about 30 to 60 minutes before
• Acetaminophen (Tylenol) — also given as a premedication

These medications help prevent or reduce infusion-related reactions. Even with premedication, the infusion nurse will monitor vital signs throughout and may adjust the infusion rate if symptoms develop.

A typical Ocrevus appointment takes about 4 to 5 hours when accounting for premedication administration, the infusion itself, and a one-hour post-infusion observation period. Patients should plan for essentially a half-day commitment.

Ocrevus Side Effects

The most commonly reported side effects in clinical trials include:

• Infusion-related reactions — the most frequent side effect, occurring in 34% to 40% of patients, predominantly during the first infusion. Symptoms include throat irritation, flushing, itching, rash, low blood pressure, fever, and headache.
• Upper respiratory tract infections
• Skin infections (herpes-related infections were more common in clinical trials)
• Lower respiratory tract infections
• Cough
• Diarrhea

Infusion reactions tend to be most common and most noticeable during the very first infusion and typically decrease significantly with subsequent treatments. The National Institute of Neurological Disorders and Stroke notes that most infusion reactions are mild to moderate and manageable with rate adjustments and additional medications.

Long-Term Immunoglobulin Monitoring

Because Ocrevus depletes B cells, long-term use may lead to decreased immunoglobulin (antibody) levels over time. Some neurologists monitor immunoglobulin G (IgG) levels periodically, particularly in patients who experience recurrent infections. This is an area of ongoing research and clinical attention.

PML and Other Serious Risks

Other serious risks associated with Ocrevus include:

• Hepatitis B reactivation — Screening for hepatitis B is required before starting treatment. Patients with active hepatitis B should not receive Ocrevus.
• Increased infection risk — Serious bacterial, viral, and fungal infections have been reported, including fatal cases. Patients should not begin Ocrevus while they have an active infection.
• Possible increased malignancy risk — A slightly higher rate of breast cancer was observed in the Ocrevus clinical trials compared to placebo/comparator groups. Patients should follow standard cancer screening guidelines, including mammography.

The Mayo Clinic recommends that patients on Ocrevus maintain regular follow-up with their neurologist, stay current on recommended health screenings, and promptly report infections or unusual symptoms.

Ocrevus vs. Kesimpta: The Anti-CD20 Conversation

Kesimpta (ofatumumab) is another anti-CD20 therapy for relapsing MS, but it is administered as a monthly subcutaneous injection rather than an IV infusion. Both medications target the same protein on B cells, though they are different molecules. For a full comparison, visit the Ocrevus vs. Kesimpta guide.

Key differences patients often weigh:

Some patients prefer the infrequency of Ocrevus: two appointments per year and the treatment is handled. Others prefer the independence of self-injecting Kesimpta at home without needing IV access or premedication. Neither is objectively better; the right choice depends on individual priorities and which form of MS has been diagnosed, since Ocrevus remains the only anti-CD20 therapy approved for PPMS.

Ocrevus Home Infusion

Home infusion for Ocrevus has gained significant traction in recent years. The every-six-month schedule means patients only need two home visits per year for their infusions, which makes the logistical coordination more manageable than medications requiring more frequent dosing.

Ocrevus home infusion eligibility typically requires:

• At least one prior infusion tolerated without significant reactions in a clinical setting
• No history of severe infusion-related reactions
• Approval from the prescribing neurologist
• Insurance authorization for home administration

A registered nurse administers the premedication and infusion at the patient’s home, monitors vital signs throughout, and stays for the observation period. The entire visit typically lasts 5 to 6 hours. Learn more about how home infusion works for various conditions and medications, or explore the specific considerations for MS home infusion therapies.